Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX.DL)

CAPS Rating: No stars

A biopharmaceutical company building an oncology business by developing and commercializing innovative therapies that target the molecular mechanisms implicated in cancer.

Recs

2
Player Avatar pick1998 (82.14) Submitted: 2/24/2009 7:39:22 AM : Outperform Start Price: $32.27 ONXX.DL Score: +163.28

ONXX reports strong revenue growth on Nexavar sales. 2008 Nexava Net sales of $678M, 82% annual growth, makes 2008 the first full year profitable although more R&D cost. New indications are progressing well. A long position for a long time.

Featured Broker Partners


Advertisement